NR1D1 Suppresses Retinoblastoma Growth via the ROS/AKT/mTOR Axis: Therapeutic Implications of REV-ERBα Agonism

Purpose: To investigate clock gene expression in retinoblastoma (RB) and explore the role and mechanism of nuclear receptor subfamily 1 group D member 1 (NR1D1) in RB progression. Methods: Bioinformatics analysis of the GSE58780 dataset was used to identify differentially expressed genes and clock genes in RB. The level of NR1D1 in RB tissues and cells was determined by qPCR, Western blot, and immunohistochemistry. Its role in RB was explored through gain-of-function and loss-of-function experiments. Cell growth, migration, invasion, and apoptosis were evaluated by CCK-8, EdU, Transwell, and flow cytometry. ROS levels and AKT/mTOR pathway activation were measured by flow cytometry and Western blot. A xenograft model of RB was established to explore the role of SR9009 in vivo. Results: In RB samples, clock genes CRY1, NR1D1, NR2E3, and TOX were significantly downregulated, while TIMELESS was upregulated. NR1D1 was confirmed to be significantly reduced in RB tissues. NR1D1 knockdown enhanced RB cell proliferation, migration, and invasion and inhibited apoptosis. In addition, ROS levels and the AKT/mTOR pathway was inhibited by NR1D1. In vivo, NR1D1 agonist SR9009 markedly restrained tumor growth, promoted apoptosis, and reduced AKT and mTOR phosphorylation. Conclusion: Clock genes are abnormally expressed in RB, with NR1D1 significantly downregulated. NR1D1 regulates RB growth through the ROS/AKT/mTOR pathway, and its agonist SR9009 inhibits RB tumor growth by activating NR1D1. These findings provide a potential therapeutic target for RB treatment.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11409783/v1
Primary Topic
Ocular Oncology and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

NR1D1 Suppresses Retinoblastoma Growth via the ROS/AKT/mTOR Axis: Therapeutic Implications of REV-ERBα Agonism

Yinan Han, Lu Gan, Jinghan Wang, Rui Huang et al.
1 links
Research Square
Ocular Oncology and Treatments
preprint

NR1D1 Suppresses Retinoblastoma Growth via the ROS/AKT/mTOR Axis: Therapeutic Implications of REV-ERBα Agonism

Yinan Han, Lu Gan, Jinghan Wang, Rui Huang, Jie Ding, Jiang Qian
preprint en

Abstract

Purpose: To investigate clock gene expression in retinoblastoma (RB) and explore the role and mechanism of nuclear receptor subfamily 1 group D member 1 (NR1D1) in RB progression. Methods: Bioinformatics analysis of the GSE58780 dataset was used to identify differentially expressed genes and clock genes in RB. The level of NR1D1 in RB tissues and cells was determined by qPCR, Western blot, and immunohistochemistry. Its role in RB was explored through gain-of-function and loss-of-function experiments. Cell growth, migration, invasion, and apoptosis were evaluated by CCK-8, EdU, Transwell, and flow cytometry. ROS levels and AKT/mTOR pathway activation were measured by flow cytometry and Western blot. A xenograft model of RB was established to explore the role of SR9009 in vivo. Results: In RB samples, clock genes CRY1, NR1D1, NR2E3, and TOX were significantly downregulated, while TIMELESS was upregulated. NR1D1 was confirmed to be significantly reduced in RB tissues. NR1D1 knockdown enhanced RB cell proliferation, migration, and invasion and inhibited apoptosis. In addition, ROS levels and the AKT/mTOR pathway was inhibited by NR1D1. In vivo, NR1D1 agonist SR9009 markedly restrained tumor growth, promoted apoptosis, and reduced AKT and mTOR phosphorylation. Conclusion: Clock genes are abnormally expressed in RB, with NR1D1 significantly downregulated. NR1D1 regulates RB growth through the ROS/AKT/mTOR pathway, and its agonist SR9009 inhibits RB tumor growth by activating NR1D1. These findings provide a potential therapeutic target for RB treatment.

Research Square
Eye & ENT Hospital of Fudan University (CN)
Good health and well-being
Ocular Oncology and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon